Plain-English translation of NCT06562413 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying people with frequent migraines who have tried multiple preventive medications without success. Researchers will use two types of brain imaging — EEG (which measures electrical activity) and MRI (which shows brain structure and blood flow) — to understand how the brain changes when patients are treated with monoclonal antibodies directed against calcitonin gene related peptide pathway (), a newer class of migraine preventive medication. By comparing brain scans from people whose migraines improve with this treatment to those whose migraines don't improve, the researchers hope to identify why some patients respond and others don't.
Many people with chronic or frequent migraines have already tried three or more different preventive medications without relief, and even newer treatments don't work for everyone. This study exists to understand the underlying biology of why some patients are resistant to treatment, which could lead to better ways to predict who will benefit from a medication and to discover new targets for future treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic at baseline (before starting the medication) and again after 3 months of treatment. At each visit, you'll have a brain EEG recording where you'll sit quietly with your eyes open and closed for about 24 minutes total. If you're one of 40 participants selected for the full study, you'll also have an MRI brain scan at the baseline visit. The EEG and MRI are non-invasive and painless — you'll simply lie still while the machines record your brain activity. The medication itself (the treatment) will be given separately as part of your regular migraine care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborators
University of L'Aquila
Enrollment target
~100 participants
Started
May 2023
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Roberto De Icco
IRCCS National Neurological Institute "C. Mondino" Foundation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.